propofol

Product NDC
25021-608
11-digit product format
250210608
Labeler code
25021
Product ID
25021-608_24f96546-ad32-43ca-be91-5536e26d4137
Type
HUMAN PRESCRIPTION DRUG
Nonproprietary name
propofol
Dosage form
INJECTION, EMULSION
Route
INTRAVENOUS
Labeler
Sagent Pharmaceuticals
Application
ANDA075102
Marketing category
ANDA
Marketing start
2014-07-01
Substance
PROPOFOL
Active strength
10 mg/mL
Pharmacologic classes
General Anesthesia [PE], General Anesthetic [EPC]
NDC exclude flag
No
Listing certified through
2026-12-31
Current FDA listing
Yes

Orange Book products#

Application-product, Trade name, Ingredient table
Application-productTrade nameIngredientStrengthDosage form / routeTE codesRLD / RSApproval date
A075102-001PROPOFOLPROPOFOL10MG/MLINJECTABLE / INJECTIONAB1999-01-04

Therapeutic equivalence codes#

Application-product, TE code table
Application-productTE code
A075102-001AB

openFDA label cross-check#

Cross-check layer: openFDA label JSON enriches search and identifies hydration gaps. The DailyMed Structured Product Label remains the canonical label presentation on FDA.report.

Brand, Generic, Manufacturer table
BrandGenericManufacturerSPL set IDEffective dateAvailable safety fieldsJoin
propofolPROPOFOLSagent Pharmaceuticalsfa93f173-7858-4d88-860e-76ab97e65c2f2025-06-07Warnings, Adverse reactionsExact identifier

Warnings cross-check#

openFDA text is shown for search and cross-checking; DailyMed SPL is canonical.

warnings and cautions

5 WARNINGS AND PRECAUTIONS Hypersensitivity Reactions : Serious and sometimes fatal reactions ( 5.1 ) Microbial Contamination : Strict aseptic technique must be maintained during handling. Propofol injectable emulsion vials are never to be accessed more than once or used on more than one person. Administration should commence promptly and be completed within 12 hours after the vial has been opened. Discard unused drug product. Do not use if contamination is suspected ( 5.2 ) Cardiovascular depression : Cases of bradycardia, asystole, and cardiac arrest have been reported. Pediatric patients are susceptible to this effect, particularly when fentanyl is given concomitantly ( 5.4 ) 5.1 Anaphylactic and Anaphylactoid Reactions Use of propofol injectable emulsion has been associated with both fatal and life threatening anaphylactic and anaphylactoid reactions. Clinical features of anaphylaxis, including angioedema, bronchospasm, erythema, and hypotension, occur rarely following propofol injectable emulsion administration. Contains sodium metabisulfite, a sulfite that may cause allergic-type reactions including anaphylactic symptoms and life-threatening or less severe asthmatic episodes in certain susceptible people. The overall prevalence of sulfite sensitivity in the general population is unknown and probably low. Sulfite sensitivity is seen more frequently in asthmatic than in nonasthmatic people. 5.2 Risks of Microbial Contamination Strict aseptic technique must always be maintained during handling. Propofol injectable emulsion is a single-dose parenteral product (single patient infusion vial) which contains sodium metabisulfite (0.25 mg per mL) to inhibit the rate of growth of microorganisms, for up to 12 hours, in the event of accidental extrinsic contamination. However, propofol injectable emulsion can still support the growth of microorganisms, as it is not an antimicrobially preserved product under USP standards. Do not use if contamination is suspected. Discard unused drug product as directed within the required time limits. There have been reports in which failure to use aseptic technique when handling propofol injectable emulsion was associated with microbial contamination of the product and with fever, infection/sepsis, other life-threatening illness, and/or death. Propofol injectable emulsion vials are never to be accessed more than once or used o...

Adverse reactions cross-check#

openFDA text is shown for search and cross-checking; DailyMed SPL is canonical.

adverse reactions

6 ADVERSE REACTIONS The following serious or otherwise important adverse reactions are discussed elsewhere in the labeling: Hypersensitivity reaction [see Warnings and Precautions ( 5.1 )] Hypotension and/or bradycardia [see Warnings and Precautions ( 5.4 )] Propofol Infusion Syndrome [see Warnings and Precautions ( 5.9 )] In the description below, rates of the more common events represent US/Canadian clinical study results. Less frequent events are also derived from publications and marketing experience in over 8 million patients; there are insufficient data to support an accurate estimate of their incidence rates. These studies were conducted using a variety of premedicants, varying lengths of surgical/diagnostic procedures, and various other anesthetic/sedative agents. Most adverse events were mild and transient. The most common adverse reactions >1% were bradycardia, arrhythmia, tachycardia, hypotension, hypertension, decreased cardiac output, movement, apnea, respiratory acidosis during weaning, rash, pruritus, burning/stinging or pain at injection site, and hyperlipemia ( 6 ) To report SUSPECTED ADVERSE REACTIONS, contact Sagent Pharmaceuticals at 1-866-625-1618 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch . Clinical Trials Experience Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice. Anesthesia and MAC Sedation in Adults The following estimates of adverse events for propofol injectable emulsion include data from clinical trials in general anesthesia/MAC sedation (N=2889 adult patients). The adverse events listed below as probably causally related are those events in which the actual incidence rate in patients treated with propofol injectable emulsion was greater than the comparator incidence rate in these trials. Therefore, incidence rates for anesthesia and MAC sedation in adults generally represent estimates of the percentage of clinical trial patients which appeared to have probable causal relationship. The adverse experience profile from reports of 150 patients in the MAC sedation clinical trials is similar to the profile established with propofol injectable emulsion during anesthesia (see Table 2 below). During MAC sedation clinic...

adverse reactions table

Table 2. Treatment Emergent Adverse Events Observed from Clinical Trials Anesthesia/MAC SedationICU SedationBody as a Whole: Anaphylaxis/Anaphylactoid reaction perinatal disorder, tachycardia, bigeminy, bradycardia, premature ventricular contractions, hemorrhage, ECG abnormal arrhythmia atrial, fever, extremities pain, anticholinergic syndrome, asthenia, awareness, chest pain, extremities pain, fever, increased drug effect, neck rigidity/stiffness, trunk pain Fever, sepsis, trunk pain, whole body weakness Cardiovascular: Premature atrial contractions Syncope, hypotension [see also Clinical Pharmacology (12)], tachycardia Nodal, arrhythmia Bradycardia, arrhythmia, atrial fibrillation, atrioventricular heart block, bigeminy, bleeding, bundle branch block, cardiac arrest, ECG abnormal, edema, extrasystole, heart block, hypertension, myocardial infarction, myocardial ischemia, premature ventricular contractions, ST segment depression, supraventricular tachycardia, tachycardia, ventricular fibrillation Bradycardia, decreased cardiac output, arrhythmia, atrial fibrillation, bigeminy, cardiac arrest, extrasystole, right heart failure, ventricular tachycardia Central Nervous System: Hypertonia/Dystonia, paresthesia, movement, abnormal dreams, agitation, amorous behavior, anxiety, bucking/jerking/thrashing, chills/shivering/clonic/myoclonic movement, combativeness, confusion, delirium, depression, dizziness, emotional lability, euphoria, fatigue, hallucinations, headache, hypotonia, hysteria, insomnia, moaning, neuropathy, opisthotonos, rigidity, seizures, somnolence, tremor, twitching Agitation, hypotension, hills/shivering, intracranial hypertension, seizures, somnolence, thinking abnormal Digestive: Hypersalivation, nausea, cramping, diarrhea, dry mouth, enlarged parotid, nausea, swallowing, vomiting Ileus, liver function abnormal Hemic/Lymphatic: Leukocytosis, coagulation disorder, leukocytosis Injection Site: Phlebitis, pruritus, burning/Stinging or pain, hives/itching, phlebitis, redness/discoloration Metabolic/Nutritional: hypomagnesemia, hyperkalemia, hyperlipemia BUN increased, creatinine increased, dehydration, hyperglycemia, metabolic acidosis, osmolality increased, hyperlipemia Musculoskeletal: Myalgia Nervous: Dizziness, agitation, chills, somnolence Delirium Respiratory: Wheezing, cough, laryngospasm, hypoxia, apnea, bronchospasm, burning in throat, ...

Additional Listing Data#

Finished product
Yes
Brand name base
propofol
Listing expiration
2026-12-31

Active Ingredients#

Ingredient, Strength table
IngredientStrength
PROPOFOL10 mg/mL

Harmonized Identifiers#

Field, Values table
FieldValues
UniiYI7VU623SF
Rxcui1808217, 1808222, 1808224

DailyMed Product Concepts#

Product concept, Relation, Version table
Product conceptRelationVersionEffective
b5dd1a36-1efc-430d-94c2-9f49a850da5fProduct name620250317
baf7f49c-75b6-496b-a00e-8e766a8e4f03Product name120210127
ebc62596-fc97-4d03-9483-7ba095d25db7Product name120151210
0ca1d589-929b-4b33-bc5b-1d84abdafa6aProduct name120150324
fc363c46-397b-4476-ac0f-70e43e8e4592Product name120150324

DailyMed Package Descriptions#

Package NDC, Product, Description table
Package NDCProductDescriptionFormQuantityStrengthSPL version
25021-608-20propofol20 mL in 1 VIALINJECTION, EMULSION2010
25021-608-20propofol25 in 1 CARTONINJECTION, EMULSION2510
25021-608-50propofol20 in 1 CARTONINJECTION, EMULSION2010
25021-608-50propofol50 mL in 1 VIALINJECTION, EMULSION5010
25021-608-51propofol100 mL in 1 VIALINJECTION, EMULSION10010
25021-608-51propofol10 in 1 CARTONINJECTION, EMULSION1010

DailyMed Billing Units#

Package NDC, Billing unit, Product NDC table
Package NDCBilling unitProduct NDCDailyMed indexing SPLSPL versionEffective
25021-608-20ML - Milliliter25021-6084e2e8ce2-ea05-458a-8695-4d82162ef1b312014-12-01
25021-608-50ML - Milliliter25021-6082c251ea1-2608-44c4-89e3-125a478aa6ce12015-04-03
25021-608-51ML - Milliliter25021-6085a9f2202-bed2-4aff-b2f7-38306a07141f12014-11-05

DailyMed Socrata Ingredients#

Ingredient, Type, UNII table
IngredientTypeUNIIDailyMed labelSPL versionUploaded
propofolACTIVE INGREDIENTYI7VU623SFPROPOFOL INJECTION, EMULSION [SAGENT PHARMACEUTICALS]3
propofolACTIVE MOIETYYI7VU623SFPROPOFOL INJECTION, EMULSION [SAGENT PHARMACEUTICALS]3
egg phospholipidsINACTIVE INGREDIENT1Z74184RGVPROPOFOL INJECTION, EMULSION [SAGENT PHARMACEUTICALS]3
glycerinINACTIVE INGREDIENTPDC6A3C0OXPROPOFOL INJECTION, EMULSION [SAGENT PHARMACEUTICALS]3
sodium hydroxideINACTIVE INGREDIENT55X04QC32IPROPOFOL INJECTION, EMULSION [SAGENT PHARMACEUTICALS]3
sodium metabisulfiteINACTIVE INGREDIENT4VON5FNS3CPROPOFOL INJECTION, EMULSION [SAGENT PHARMACEUTICALS]3
soybean oilINACTIVE INGREDIENT241ATL177APROPOFOL INJECTION, EMULSION [SAGENT PHARMACEUTICALS]3

DailyMed Dashboard NDC Coverage#

NDC, Dashboard title, SPL version table
NDCDashboard titleSPL versionValidationDashboard ZIP
25021-608PROPOFOL INJECTION, EMULSION [SAGENT PHARMACEUTICALS]9Current NDC, Legacy NDC, 6 package rows20230629_fa93f173-7858-4d88-860e-76ab97e65c2f.zip

DailyMed RxNorm Mappings#

RxCUI, RxNorm string, TTY table
RxCUIRxNorm stringTTYDailyMedSPL version
1808217propofol 1000 MG in 100 ML InjectionPSNfa93f173-7858-4d88-860e-76ab97e65c2f10
1808224propofol 200 MG in 20 ML InjectionPSNfa93f173-7858-4d88-860e-76ab97e65c2f10
1808222propofol 500 MG in 50 ML InjectionPSNfa93f173-7858-4d88-860e-76ab97e65c2f10
1808217100 ML propofol 10 MG/ML InjectionSCDfa93f173-7858-4d88-860e-76ab97e65c2f10
180822420 ML propofol 10 MG/ML InjectionSCDfa93f173-7858-4d88-860e-76ab97e65c2f10
180822250 ML propofol 10 MG/ML InjectionSCDfa93f173-7858-4d88-860e-76ab97e65c2f10
1808217propofol 1000 MG per 100 ML InjectionSYfa93f173-7858-4d88-860e-76ab97e65c2f10
1808224propofol 200 MG per 20 ML InjectionSYfa93f173-7858-4d88-860e-76ab97e65c2f10
1808222propofol 500 MG per 50 ML InjectionSYfa93f173-7858-4d88-860e-76ab97e65c2f10

Packages#

Package NDC, 11-digit format, Description table
Package NDC11-digit formatDescriptionUnitsMarketing startMarketing endSampleExclude flagStatus
25021-608-202502106082025 VIAL in 1 CARTON (25021-608-20) / 20 mL in 1 VIAL25 vial2014-07-010000-00-00NoNoCurrent
25021-608-502502106085020 VIAL in 1 CARTON (25021-608-50) / 50 mL in 1 VIAL20 vial2014-07-010000-00-00NoNoCurrent
25021-608-512502106085110 VIAL in 1 CARTON (25021-608-51) / 100 mL in 1 VIAL10 vial2014-07-010000-00-00NoNoCurrent